ROZLYTREK HARD CAPSULE 100MG

Catalent Greenville, Inc. (UNITED STATES)F. Hoffmann-La Roche Ltd (Primary and secondary packaging) (SWITZERLAND)Recipharm Leganés S.L.U. (SPAIN)🇸🇬 Health Sciences Authority

Approval Date: Jan 27, 2021
Approval ID: 236b43759ac2da63
Company: Catalent Greenville, Inc. (UNITED STATES)F. Hoffmann-La Roche Ltd (Primary and secondary packaging) (SWITZERLAND)Recipharm Leganés S.L.U. (SPAIN)
Type: Therapeutic

Approval Details

Approval Id: 236b43759ac2da63
Drug Name: ROZLYTREK HARD CAPSULE 100MG
Product Name: ROZLYTREK HARD CAPSULE 100MG
Approval Number: SIN16086P
Approval Date: 2021-01-27
Registrant: ROCHE SINGAPORE PTE. LTD.
Licence Holder: ROCHE SINGAPORE PTE. LTD.
Drug Type: Therapeutic
Forensic Classification: Prescription Only
Dosage Form: CAPSULE
Dosage: 2.2 DOSAGE AND ADMINISTRATION General Patient Selection Solid Tumors A validated assay is required for the selection of patients with NTRK fusion-positive locally advanced or metastatic solid tumors. NTRK fusion-positive status should be established prior to initiation of Rozlytrek therapy. NSCLC A validated assay is required for the selection of patients with ROS1-positive locally advanced or metastatic NSCLC. ROS1-positive status should be established prior to initiation of Rozlytrek therapy. Dosage Rozlytrek hard capsules can be taken with or without food, swallowed whole and must not be opened or dissolved. Adults The recommended dose of Rozlytrek for adults is 600 mg given orally, once daily (see section 3.2 Pharmacokinetic Properties – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Pediatric patients 12 years and older The recommended dose of Rozlytrek for pediatric patients, 12 years and older, who have the ability to swallow capsules is 300 mg/m2 orally, once daily (see Table 1). (See section 3.2 Pharmacokinetic Properties – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). <img src="/TGIF/Rozlytrek-Table1.png" alt="Rozlytrek Dosage Table 1" /> Duration of Treatment It is recommended that patients are treated with Rozlytrek until disease progression or unacceptable toxicity. Delayed or Missed Doses If a planned dose of Rozlytrek is missed, patients can make up that dose unless the next dose is due within 12 hours. If vomiting occurs immediately after taking a dose of Rozlytrek, patients may repeat that dose. Dose Modifications Management of adverse events may require temporary interruption, dose reduction, or discontinuation of treatment with Rozlytrek, based on the prescriber’s assessment of the patient’s safety or tolerability. Adults For adults, the dose of Rozlytrek may be reduced up to 2 times, based on tolerability. Table 2 provides general dose reduction advice for adult patients. Rozlytrek treatment should be permanently discontinued if patients are unable to tolerate a dose of 200 mg once daily. <img src="/TGIF/Rozlytrek-Table2.png" alt="Rozlytrek Dosage Table 2" /> Pediatric Patients Table 3 provides specific dose reduction advice for pediatric patients. For pediatric patients, the dose of Rozlytrek may be reduced up to 2 times, based on tolerability. For some patients an intermittent dosing schedule is required to achieve the recommended reduced total weekly pediatric dose. Rozlytrek treatment should be permanently discontinued if patients are unable to tolerate the lowest reduced dose. <img src="/TGIF/Rozlytrek-Table3.png" alt="Rozlytrek Dosage Table 3" /> Dose Modifications for Specific Adverse Reactions Recommendations for Rozlytrek dose modifications for adults and pediatric patients for specific adverse reactions are provided in Table 4. (See section 2.4.1 Warnings and Precautions and section 2.6 Undesirable Effects – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). <img src="/TGIF/Rozlytrek-Table4a_101121.png" alt="Rozlytrek Dosage Table 4" /> <img src="/TGIF/Rozlytrek-Table4b_101121.png" alt="Rozlytrek Dosage Table 4" /> <img src="/TGIF/Rozlytrek-Table4c_101121.png" alt="Rozlytrek Dosage Table 4" /> Dose Modifications for Specific Drug Interactions Concomitant strong or moderate CYP3A inhibitors: Adults The concomitant use of strong or moderate CYP3A inhibitors and Rozlytrek in adults should be avoided or limited to 14 days or less. If concomitant use of strong or moderate CYP3A inhibitors cannot be avoided, Rozlytrek dose should be reduced to 100 mg once daily for use with strong CYP3A inhibitors and to 200 mg once daily for use with moderate CYP3A inhibitors. After discontinuation of the concomitant strong or moderate CYP3A inhibitors, Rozlytrek dose that was taken prior to initiating the strong or moderate CYP3A inhibitor can be resumed. A wash out period may be required for CYP3A4 inhibitors with long half-life. (See section 2.8 Interactions with Other Medicinal Products and other forms of Interaction – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Pediatric patients The concomitant use of strong or moderate CYP3A inhibitors in pediatric patients should be avoided. (See section 2.8 Interactions with Other Medicinal Products and other forms of Interaction – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Concomitant CYP3A inducers: Co-administration of Rozlytrek with CYP3A inducers in adult and pediatric patients should be avoided. (See section 2.8 Interactions with Other Medicinal Products and other forms of Interaction – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). 2.2.1 Special Dosage Instructions Pediatric use Pediatric patients must have the ability to swallow whole Rozlytrek capsules. Dosage for patients 12 years and older is based on body surface area (mg/m2) with a maximum daily dose of 600 mg (see Table 1 for pediatric dosing). The safety and efficacy of Rozlytrek in children below 12 years of age have not been established. Geriatric use No dose adjustment of Rozlytrek is required in patients ≥ 65 years of age. (See section 3.2.5 Pharmacokinetics in Special Populations – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Renal Impairment No dose adjustment is required in patients with mild or moderate renal impairment. The safety and efficacy of Rozlytrek have not been studied in patients with severe renal impairment. (See sections 2.5 Use in Special Populations and section 3.2.5 Pharmacokinetics in Special Populations – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Hepatic Impairment No dose adjustment is required in patients with underlying mild, moderate or severe hepatic impairment based on a study in subjects with hepatic impairment. (See section 2.5 Use in Special Populations and section 3.2.5 Pharmacokinetics in Special Populations – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Patients with severe hepatic impairment should be carefully monitored for hepatic function and adverse reactions (see Table 4). Other Special Patient Populations Ethnicity No dose adjustment is necessary for patients of different ethnicities (see section 3.2.5 Pharmacokinetics in Special Populations – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Route Of Administration: ORAL
Indication Info: 2.1 THERAPEUTIC INDICATION(S) Solid tumors Rozlytrek is indicated for the treatment of adult and pediatric patients 12 years of age and older, with neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumors without a known acquired resistance mutation, that are locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have progressed following prior therapies or have no satisfactory alternative treatments. Non-small cell lung cancer (NSCLC) Rozlytrek is indicated for the treatment of adult patients with ROS1-positive, locally advanced or metastatic NSCLC.
Contraindications: 2.3 CONTRAINDICATIONS Rozlytrek is contraindicated in patients with a known hypersensitivity to entrectinib or any of the excipients.
Atc Code: L01XE56
Atc Item Name: xl 01 xe 56
Pharma Manufacturer Name: ROCHE SINGAPORE PTE. LTD.

Active Ingredients

Entrectinib (Form A) or (Form C)

100.000mg

Entrectinib (Form A) or (Form C)

100.000mg

Approved

Quick Info

Agency

HSA

Country

🇸🇬

Approval Date

Jan 27, 2021

Approval ID

236b43759ac2da63

Type

Therapeutic

Back to HSA Approvals